ArticlePharmaceutics2023

Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG.

Maria Victoria Sanchez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.